Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Madrigal Pharmaceuticals Inc (NQ: MDGL ) 217.00 +4.57 (+2.15%) Streaming Delayed Price Updated: 9:57 AM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Madrigal Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > 2 Top Biotech Buyout Candidates March 31, 2024 Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... Via Talk Markets Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals March 29, 2024 Both stocks are pretty risky, but one of them more so than the other. Via The Motley Fool Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? March 29, 2024 Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off? Via The Motley Fool 7 Stocks That Will Drive the Weight Loss Drugs Market March 28, 2024 The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. Via MarketBeat Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock March 26, 2024 This biotech just got clearance to dive into a deep ocean of a market. Via The Motley Fool Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading March 15, 2024 Via Investor Brand Network Madrigal Pharmaceuticals: Q4 Earnings Insights February 28, 2024 Via Benzinga This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? March 22, 2024 The mid-cap biotech has succeeded where many others failed. Via The Motley Fool Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? March 19, 2024 Madrigal has one key advantage over its two huge potential future rivals. Via The Motley Fool Exposures Product Safety 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark March 18, 2024 On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. Via Investor's Business Daily 10 Health Care Stocks Whale Activity In Today's Session March 18, 2024 Via Benzinga Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? March 17, 2024 Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. Via The Motley Fool Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 15, 2024 Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. Via Benzinga FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring March 15, 2024 FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... Via Benzinga Exposures Product Safety Why Is Geron (GERN) Stock Up 94% Today? March 15, 2024 Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. Via InvestorPlace Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday March 15, 2024 U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... Via Benzinga Topics Stocks Exposures US Equities MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today March 15, 2024 Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. Via InvestorPlace Exposures Product Safety 12 Health Care Stocks Moving In Friday's Pre-Market Session March 15, 2024 Via Benzinga Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket March 15, 2024 Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday March 15, 2024 It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! Via InvestorPlace 12 Health Care Stocks Moving In Thursday's After-Market Session March 14, 2024 Via Benzinga Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session March 14, 2024 Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Via Benzinga Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH March 14, 2024 The company hopes to be the first to the finish line with a treatment for MASH. Via Investor's Business Daily Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. March 09, 2024 Good news could be in store for all three of these drugmakers. Via The Motley Fool 1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? March 05, 2024 This business could be on the cusp of making medical history. Via The Motley Fool Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena February 26, 2024 The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. Via Investor's Business Daily 1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street February 23, 2024 The company might have a bright future, but is now the right time to buy shares? Via The Motley Fool Analysts see over 50% gains in these 2 mid-cap biotech stocks February 14, 2024 The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence COVID-19 Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug February 08, 2024 The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.